FDA Oncologic Drugs Advisory Committee Votes in Favor of Cilta-Cel as Early Treatment for Multiple Myeloma

The FDA’s ODAC sought to determine whether cilta-cel has a favorable benefit-risk profile for patients with multiple myeloma. The FDA’s ODAC unanimously voted that the potential benefits of cilta-cel outweigh its risks for its proposed indication in patients with multiple myeloma.

Related Keywords

United States , Irene Ghobrial , Helkha Peredo Pinto , Ravi Madan , Susan Lattimore , Mary Kwok , University Of Washington School Medicine , Drug Administration , Janssen Pharmaceutical Companies Of Johnson , Janssen Biotech Inc , Dana Farber Cancer Institute , Oncologic Drugs Advisory Committee , Harvard Medical School , Biologics Licensing Application , Janssen Biotech , Janssen Pharmaceutical Companies , Washington School ,